

Soizic Garaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1800668/publications.pdf>

Version: 2024-02-01

38
papers

2,808
citations

257450

24
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

5189
citing authors

#	ARTICLE	IF	CITATIONS
1	CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892.	8.2	813
2	CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight, 2017, 2, .	5.0	258
3	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	5.0	182
4	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. OncoImmunology, 2017, 6, e1257452.	4.6	169
5	IL-6 Modulates CD5 Expression in B Cells from Patients with Lupus by Regulating DNA Methylation. Journal of Immunology, 2009, 182, 5623-5632.	0.8	156
6	DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. Journal of Clinical Investigation, 2017, 127, 3090-3102.	8.2	110
7	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	5.5	81
8	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	4.8	80
9	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	6.3	76
10	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	70
11	CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation. Journal of Immunology, 2011, 186, 4835-4844.	0.8	65
12	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	4.8	65
13	Immunity drives <i>TET1</i> regulation in cancer through NF- κ B. Science Advances, 2018, 4, eaap7309.	10.3	64
14	Selection of the Alternative Exon 1 from the <i>cd5</i> Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes. Journal of Immunology, 2008, 181, 2010-2018.	0.8	48
15	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335.	12.8	46
16	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cellular and Molecular Immunology, 2018, 15, 158-170.	10.5	45
17	Lymphoproliferative Disorders Associated With Hypereosinophilia. Seminars in Hematology, 2012, 49, 138-148.	3.4	37
18	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine, 2019, 39, 226-238.	6.1	36

#	ARTICLE	IF	CITATIONS
19	FOXP1 is a regulator of quiescence in healthy human CD4 ⁺ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. <i>European Journal of Immunology</i> , 2017, 47, 168-179.	2.9	35
20	Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. <i>Immunology</i> , 2007, 122, 371-380.	4.4	33
21	CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. <i>Autoimmunity Reviews</i> , 2012, 11, 795-798.	5.8	33
22	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	33
23	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. <i>Cancer Letters</i> , 2019, 450, 88-97.	7.2	33
24	Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. <i>BMC Cancer</i> , 2020, 20, 135.	2.6	32
25	T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. <i>Nature Communications</i> , 2022, 13, 2259.	12.8	32
26	Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. <i>Nature Cancer</i> , 2021, 2, 611-628.	13.2	30
27	IL-10 Production by B Cells Expressing CD5 with the Alternative Exon 1B. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 280-285.	3.8	28
28	Autoreactive B Cells and Epigenetics. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 39, 85-94.	6.5	24
29	Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis. <i>Cancer Research</i> , 2019, 79, 5826-5838.	0.9	21
30	DNA Methylation and B-Cell Autoreactivity. <i>Advances in Experimental Medicine and Biology</i> , 2011, 711, 50-60.	1.6	20
31	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 673042.	3.5	19
32	IRF5: a rheostat for tumor-infiltrating lymphocyte trafficking in breast cancer?. <i>Immunology and Cell Biology</i> , 2015, 93, 425-426.	2.3	9
33	Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients. <i>BMC Cancer</i> , 2019, 19, 81.	2.6	9
34	Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. <i>Methods in Molecular Biology</i> , 2018, 1845, 139-157.	0.9	6
35	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	3.7	6
36	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. <i>Acta Clinica Belgica</i> , 2021, 76, 144-148.	1.2	2

#	ARTICLE	IF	CITATIONS
37	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. <i>Diagnostics</i> , 2022, 12, 539.	2.6	2
38	Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenesence?. <i>Blood</i> , 2016, 128, 5983-5983.	1.4	0